Drug intelligence / Profile preview

STN1013600

Development stage: Discontinued
Lead developer: Santen Pharmaceutical
Modality: Small Molecules
Administration: Ophthalmic

Overview

STN1013600 is an ophthalmic solution of ursodeoxycholic acid (UDCA) developed by Santen for the treatment of presbyopia. Unlike traditional presbyopia treatments that utilize miotics to constrict the pupil, STN1013600 is designed as a "lens softener." Its mechanism of action aims to restore the elasticity of the crystalline lens, addressing the underlying age-related stiffening that causes near-vision impairment. The drug was evaluated in the Phase IIa OPSIS clinical trial (NCT05665387) at concentrations of 0.1% and 0.3% administered twice daily. However, in 2024, Santen discontinued the development of STN1013600 following a review of the trial data.

Other names: ursodeoxycholic acid ophthalmic solution

Targets

P-SH (Crystallin sulfhydryl group)

Beyond the preview

Go deeper on STN1013600.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on STN1013600.

Explore the full profile